ZA848156B - Compounds having antiinflammatory activity,obtained by complexation with beta-cyclodextrin,and pharmaceutical compositions containing them - Google Patents

Compounds having antiinflammatory activity,obtained by complexation with beta-cyclodextrin,and pharmaceutical compositions containing them

Info

Publication number
ZA848156B
ZA848156B ZA848156A ZA848156A ZA848156B ZA 848156 B ZA848156 B ZA 848156B ZA 848156 A ZA848156 A ZA 848156A ZA 848156 A ZA848156 A ZA 848156A ZA 848156 B ZA848156 B ZA 848156B
Authority
ZA
South Africa
Prior art keywords
compounds
complexation
cyclodextrin
beta
pharmaceutical compositions
Prior art date
Application number
ZA848156A
Other languages
English (en)
Inventor
Paolo Chiese
Vittorino Servadio
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of ZA848156B publication Critical patent/ZA848156B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
ZA848156A 1984-02-22 1984-10-18 Compounds having antiinflammatory activity,obtained by complexation with beta-cyclodextrin,and pharmaceutical compositions containing them ZA848156B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT19735/84A IT1196033B (it) 1984-02-22 1984-02-22 Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche

Publications (1)

Publication Number Publication Date
ZA848156B true ZA848156B (en) 1985-06-26

Family

ID=11160778

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA848156A ZA848156B (en) 1984-02-22 1984-10-18 Compounds having antiinflammatory activity,obtained by complexation with beta-cyclodextrin,and pharmaceutical compositions containing them

Country Status (19)

Country Link
US (1) US4603123A (enExample)
EP (1) EP0153998B1 (enExample)
JP (1) JPS60208979A (enExample)
KR (1) KR870001960B1 (enExample)
AT (1) ATE52263T1 (enExample)
AU (1) AU550007B2 (enExample)
BE (1) BE900836A (enExample)
CA (1) CA1234106A (enExample)
DE (2) DE153998T1 (enExample)
DK (1) DK164911C (enExample)
ES (1) ES536909A0 (enExample)
IE (1) IE58231B1 (enExample)
IT (1) IT1196033B (enExample)
MY (1) MY101374A (enExample)
NZ (1) NZ211114A (enExample)
PH (1) PH22075A (enExample)
PT (1) PT79997B (enExample)
SG (1) SG53690G (enExample)
ZA (1) ZA848156B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674854A (en) * 1993-10-08 1997-10-07 Farmarc Nederland Bv Inclusion complex of beta-cyclodextrin and diclofenac, its preparation and use

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
IT1204725B (it) * 1987-06-17 1989-03-10 Edmond Pharma Srl Complessi di inclusione del dipiridamolo con ciclodestrine
NZ225045A (en) * 1987-07-01 1990-06-26 Janssen Pharmaceutica Nv Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
DE3809808A1 (de) * 1988-03-23 1989-10-05 Hexal Pharma Gmbh & Co Kg Feste, insbesondere festorale und rektale, etofenamat enthaltende arzneimittel
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
IT1241088B (it) * 1990-03-27 1993-12-29 Chiesi Farma Spa Procedimento per la preparazione di complessi piroxicam/ciclodestrina,prodotti ottenuti e loro composizioni farmaceutiche
US5180716A (en) * 1990-08-01 1993-01-19 The Regents Of The University Of California Cyclodextrin complexes for neuraxial administration of drugs
EP1004318A3 (en) * 1991-06-21 2002-08-07 Takeda Chemical Industries, Ltd. Cyclodextrin composition
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US20040014695A1 (en) * 1992-06-19 2004-01-22 Supergen, Inc. Pharmaceutical formulation
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US5824668A (en) * 1996-11-07 1998-10-20 Supergen, Inc. Formulation for administration of steroid compounds
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
US6667056B2 (en) * 1997-07-23 2003-12-23 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
FR2786395A1 (fr) * 1998-12-01 2000-06-02 Virbac Sa Compositions seches solubles en presence d'eau et evitant la reaction de maillard a l'etat sec, leur preparation et leurs applications
TWI242015B (en) 1999-11-29 2005-10-21 Akzo Nobel Nv 6-mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block
WO2002045713A2 (en) * 2000-12-04 2002-06-13 Sepracor, Inc. Orally-bioavailable formulations of fentanyl and congeners thereof
GB0205253D0 (en) * 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
ATE359827T1 (de) * 2002-06-17 2007-05-15 Chiesi Farma Spa Prozess für die vorbereitung von piroxicam: beta- cyclodextrin einschlusskomplexe
EP1582221A1 (en) * 2004-03-31 2005-10-05 Chiesi S.A. Pharmaceutical oral compositions with a taste masking effect
EP2260871B1 (fr) 2004-04-01 2013-05-15 Pierre Fabre Medicament Complexes d'inclusions comprenant du piroxicam, une cyclodextrine et l'arginine
ES2277199T3 (es) * 2004-04-15 2007-07-01 Helm Ag Procedimiento para la preparacion de adsorbatos de valsartan pulverulentos de flujo libre.
US20060024922A1 (en) * 2004-07-27 2006-02-02 Da-Tung Wen Method for cutting wafer
ATE502653T1 (de) * 2004-08-02 2011-04-15 Chiesi Farma Spa Verfahren zur herstellung einer piroxicam:beta- cyclodextrin-einschlussverbindung
FR2876910B1 (fr) 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
US20070010487A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010485A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070010466A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
US20070010486A1 (en) * 2005-07-06 2007-01-11 Jeff Schwegman Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
US20070009532A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
GB0612695D0 (en) * 2006-06-27 2006-08-09 Univ Gent Process for preparing a solid dosage form
CL2007003876A1 (es) * 2007-12-28 2008-03-07 Univ De Concepcion Y Lab Andro Complejo de inclusion que esta formado por disulfiram y ciclodextrina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de la dependencia de alcohol y cocaina.
KR101383941B1 (ko) * 2012-03-09 2014-04-10 동아에스티 주식회사 피록시캄 또는 약제학적으로 허용되는 그의 염과 히알루론산 또는 약제학적으로 허용되는 그의 염의 안정한 액상 조성물 및 그 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2827452A (en) * 1955-05-31 1958-03-18 Univ Minnesota Stabilization of materials
US3969338A (en) * 1971-03-15 1976-07-13 Institut National De La Recherche Agronomique Protein obtained from cakes of vegetable origin
HU184066B (en) * 1979-12-28 1984-06-28 Chinoin Gyogyszer Es Vegyeszet Plant growth regulating substance and process for preparing such compound
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS5838250A (ja) * 1981-09-01 1983-03-05 Teikoku Chem Ind Corp Ltd 複合体
JPS58126810A (ja) * 1981-12-24 1983-07-28 Kaken Pharmaceut Co Ltd 抗炎症眼科用液剤およびその製法
JPS5920230A (ja) * 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674854A (en) * 1993-10-08 1997-10-07 Farmarc Nederland Bv Inclusion complex of beta-cyclodextrin and diclofenac, its preparation and use

Also Published As

Publication number Publication date
AU550007B2 (en) 1986-02-27
DK76085A (da) 1985-08-23
CA1234106A (en) 1988-03-15
DE153998T1 (de) 1986-04-10
DK164911B (da) 1992-09-07
DK164911C (da) 1993-01-18
EP0153998B1 (en) 1990-04-25
IE58231B1 (en) 1993-08-11
AU3892385A (en) 1985-08-29
PH22075A (en) 1988-05-20
ES8504789A1 (es) 1985-05-01
PT79997A (en) 1985-03-01
IT8419735A0 (it) 1984-02-22
NZ211114A (en) 1987-09-30
EP0153998A2 (en) 1985-09-11
PT79997B (en) 1987-01-13
KR870001960B1 (ko) 1987-10-23
BE900836A (fr) 1985-02-15
MY101374A (en) 1991-10-23
EP0153998A3 (en) 1987-01-14
IT1196033B (it) 1988-11-10
US4603123A (en) 1986-07-29
KR850006133A (ko) 1985-10-02
IE850325L (en) 1985-08-22
ATE52263T1 (de) 1990-05-15
JPH0370705B2 (enExample) 1991-11-08
DK76085D0 (da) 1985-02-19
DE3482041D1 (de) 1990-05-31
SG53690G (en) 1990-11-23
ES536909A0 (es) 1985-05-01
JPS60208979A (ja) 1985-10-21

Similar Documents

Publication Publication Date Title
EP0153998A3 (en) New compounds having antiinflammatory activity, obtained by complexation with beta-cyclodextrin, and pharmaceutical compositions containing them
AU591245B2 (en) A deodorant composition and use thereof
AU674378B2 (en) Use of 2-amino-6-A-propylamino-4,5,6, 7-tetrahydrobenzothiazole (pramipexol) as an anti-depressantdrug
FR2451192A1 (fr) Agent de prevention de la mauvaise haleine contenant de la cyclodextrine
ATE67668T1 (de) Antibakterielle creme.
EP0165458A3 (en) (+)-ambrox, process for production thereof and use thereof
ATE198400T1 (de) Biozide zusammensetzung
DE69635275D1 (de) Stabilisierte wässerige steroidimmunteststandarten mit cyclodextrins
ATE63750T1 (de) Peptid, dessen herstellung und benutzung.
EP0181166A3 (en) Solubilised platinum compounds
ES8303339A1 (es) Un procedimiento para la preparacion de 2,3-dicloro-5-triclorometilpiridina.
AU570552B2 (en) 1,4-dihydropyridine-3-carboxylates and salts thereof
DE69003585D1 (de) Anti-zahnstein zahnpasten mit erhoehter lagerfaehigkeit.
FI854450A7 (fi) Seostetun teräksen valmistus käyttäen kemiallisesti valmistettua V2O3: a vanadiinilisäaineena.
DE3687838D1 (de) Deodorant-bettmaterial.
ES8505915A1 (es) Metodo de preparar dimetiloctenonas
DE69331216D1 (de) Planze resistent gegen mindestens zwei viren und dessen preparation
JPS6463342A (en) Stabilization of glutathione-containing composition
ES8507553A1 (es) Procedimiento de preparacion de 1,1-dioxido del acido 6,6-dibromopenicilanico.
MD369C2 (ro) Imunizator chimic al plantelor de tutun
MD1492G2 (ro) Tomatozid oxidat cu proprietăţi antivirale
EP0125654A3 (en) Process for the preparation of especially pharmacologically active compounds containing a sulfoxide group
DE59009647D1 (de) Stabilisiertes Reagenzgemisch.
KR850007241A (ko) 인분을 주재로 한 고단위 비료 제법
ATE103986T1 (de) Makromolekulare complexe pflanzlichen ursprungs, ihre herstellung und verwendung als hypocholesterinaemlische verbindung.